Profiles of 13 patients with adult onset Still’s disease when methotrexate treatment was initiated
| Patient | Sex/age | Disease duration (months) | Number of items of criteria1-150 | Treatment before start of methotrexate (duration) | Number of active signs or symptoms1-151 | Laboratory data before methotrexate treatment | |||||||
| Ferritin (ng ml−1) | AST/ALT (IUl−1) | RF/ANA | HLA-DR type | ||||||||||
| 1 | F/44 | 54 | 7 | PSL 20 mg/d (2 weeks) | 4 | 290 | 16/7 | −/− | 4/4 | ||||
| 2 | F/27 | 84 | 6 | PSL 10 mg/d (4 weeks) | 3 | 51 | 10/8 | −/− | 4/4 | ||||
| 3 | M/28 | 126 | 6 | PSL 16 mg/d (2 weeks) | 6 | 1025 | 17/24 | −/− | 2/2 | ||||
| 4 | F/21 | 66 | 7 | DS 75 mg/d (3 weeks) | 4 | 183 | 57/31 | −/− | 4/4 | ||||
| 5 | M/32 | 72 | 5 | PSL 18 mg/d (2 weeks) | 5 | 348 | 21/22 | −/− | 2/4 | ||||
| 6 | M/40 | 36 | 6 | DS 75 mg/d (3 weeks) | 4 | 3300 | 19/34 | −/− | 4/4 | ||||
| 7 | M/32 | 32 | 6 | DS 75 mg/d (3 weeks) | 3 | 68 | 20/30 | −/− | 2/2 | ||||
| 8 | M/46 | 8 | 5 | DS 75 mg/d (4 weeks) | 4 | 7500 | 141/89 | −/+ | 2/9 | ||||
| 9 | F/22 | 24 | 5 | DS 75 mg/d (4 weeks) | 5 | 690 | 11/11 | −/+ | 2/6 | ||||
| 10 | F/48 | 84 | 7 | PSL 20 mg/d (4 weeks) | 3 | 91 | 21/10 | −/− | 2/5 | ||||
| 11 | F/64 | 66 | 7 | PSL 11 mg/d (5 weeks) | 3 | 745 | 28/28 | −/− | 2/5 | ||||
| 12 | M/17 | 2 | 5 | DS 75 mg/d (4 weeks) | 4 | 860 | 31/51 | −/− | 2/8 | ||||
| 13 | F/42 | 148 | 7 | PSL 10 mg/d (4 weeks) | 4 | 14 | 9/9 | −/− | 4/9 | ||||
↵1-150 The number of items in preliminary criteria for a classification6 at disease onset.
↵1-151 The number of clinical findings associated with AOSD (spiking fever, arthralgia or arthritis, typical rash, leucocytosis, sore throat, lymphadenopathy or splenomegaly, hepatomegaly or liver dysfunction, pleuritis, pericarditis) which were present in our patients before methotrexate treatment.
WBC, white blood cell count; AST/ALT, aspartate aminotransferase/alanine aminotransferase; RF, rheumatoid factor; ANA, antinuclear antibodies; PSL, prednisolone; DS, diclofenac sodium.